ClearNote Health, focused on early cancer detection, has announced findings from a cost-effectiveness analysis of the Avantect Pancreatic Cancer test for managing new-onset diabetes (NOD) patients. This analysis, conducted with the Mayo Clinic and Arizona Centers for Digestive Health, will be presented on November 19 at the ISPOR conference.
Over 80% of pancreatic cancer patients have either type 2 diabetes or impaired glucose tolerance. The test proved cost-effective in detecting early-stage pancreatic cancer in diabetes patients aged 50 and older, who are at increased risk, often diagnosed less than two years before pancreatic cancer is detected.
“This analysis is groundbreaking. Our model suggests that more patients could be identified at early stages, increasing their chances for life-saving surgery. Monitoring newly diagnosed type 2 diabetes patients aged 50 and above for pancreatic cancer using Avantect is not only potentially life-saving but also cost-effective for the healthcare system,” said David Mullarkey, CEO of ClearNote Health.
ClearNote Health aims to meet the critical need for early cancer detection in high-risk patients. Their proprietary methods use standard blood draws to identify early pancreatic cancer signals by measuring levels of 5-hydroxymethylcytosine (5hmC), copy number variants, and DNA fragment sizes.
About ClearNote Health
ClearNote Health is dedicated to early cancer detection, enabling individuals at high risk for fatal cancers to live healthier lives. Utilizing a standard blood draw, the company applies its unique epigenomic platform, integrating biology and artificial intelligence, to detect DNA changes indicative of cancer. With programs targeting non-invasive early detection of pancreatic and ovarian cancers, ClearNote identifies cancers when treatment is most beneficial. Headquartered in San Diego, the company operates a CLIA- and CAP-accredited laboratory in the area.
